Sanofi, Irbm, Reithera: Italy’s role for the anti Covid vaccine
Sanofi, Catalent, Irbm and Reithera are working on the anti Covid-19 vaccine in Italy. Here is the role that every single company has
Italy also plays a key role in the development, production and packaging of anti Covid vaccines. Today the Sanofi plant in Anagni inaugurated the production lines of the drug developed by the French Sanofi in collaboration with the British pharmaceutical company Gsk ( which also has a hand in the Tls foundation which will be financed by the Conte government ).
In Italy, the vaccine developed by the University of Oxford in collaboration with the Italian Irbm and produced by Astrazeneca will be filled at the Catalent in Anagni. And also in Italy, Reithera, owned by Keires Ag, a company in the financial sector based in Basel , has developed, in collaboration with Spallanzani, a vaccine that is tested and produced in our country.
Let's go step by step.
SANOFI STARTS VACCINE PRODUCTION IN ANAGNI
Let's start with the news on the subject. Sanofi today inaugurated the production lines for the Coronavirus vaccine candidate, developed and tested by the French group in collaboration with the British pharmaceutical company GSK, GlaxoSmithKline. It is a DNA-recombinant subunit vaccine, based on a technology already used for the production of the recombinant quadrivalent influenza vaccine that will allow the production of a significantly greater number of doses.
The Italian hub was chosen, said Alessandro Galassini, director of the Sanofi plant in Anagni, together with those of France and Germany for the production and implementation of the vaccine doses. The Anagni one "will be the first (plant, ed ) in Europe to field the vaccine", explains the company.
CATALENT
Also in Anagni, the American Catalent, a global supplier of technologies for the delivery, development, production of drugs, biological products, gene therapies and products for the health of consumers, has ignited the engines. The company has signed a contract with Astrazeneca to inflate the vaccine doses produced by Astrazeneca and developed by the University of Oxford and the Italian Irbm.
IRBM
Irbm , a company founded in 2009 in Pomezia, operating in the sector of molecular biotechnology, biomedical science and organic chemistry, led by Piero Di Lorenzo, president and CEO of the company , collaborated with the Jenner Institute of the University of Oxford at the to the point of the vaccine produced by Astrazeneca. Irbm has had a consolidated relationship with the Jenner Institute for over ten years.
ASTRAZENECA VACCINE TO EMA ASSESSMENT
The vaccine, based on an adenovirus vector, is called AZD1222 and is currently being studied by EMA. The European Medicines Agency has begun analyzing data from the Covid-19 vaccine. It is the first candidate to arrive at this stage. "The beginning of the 'rolling review – explains the EMA – means that the committee for human medicines has begun to evaluate the first set of data, which comes from laboratory studies (not from clinical data)!".
REITHERA
In Castel Romano, the Reithera plant, a biotech company controlled by Keires Ag , a company in the financial sector based in Basel, has created, developed and produced an anti Covid vaccine , in collaboration with the National Institute for Infectious Diseases, Lazzaro Spallanzani di Rome.
The vaccine has been in phase 1 trials since August 24, in Rome, at the Spallanzani institute and at the Clinical Research Center in Verona, but ReiThera is already preparing the large-scale production of the vaccine doses.
Among other things, Reithera received the first leasing loan guaranteed by Sace in Italy, while Irbm, despite the institutional forcing on CDP and government, did not obtain the support requested by Irbm's chief executive, Piero Di Lorenzo.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/innovazione/sanofi-irbm-reithera-il-ruolo-dellitalia-per-il-vaccino-anti-covid/ on Thu, 01 Oct 2020 14:00:51 +0000.